Sellas Life Sciences is trading 4.4% down at $10.84 on October 16, 2026, with no new company-specific announcement identified to explain the decline.
- Recent coverage points to investor caution ahead of the high-risk Phase 3 REGAL trial outcome; delayed results and a related investor investigation were reported before this session and are background risks, not confirmed October 16 events.
- Bearish put-option activity and existing legal-investigation alerts may also weigh on sentiment, but no new catalyst today was identified. Supplied sector context shows biotech rising and broad-market moves mixed; neither clearly accounts for the decline.